DarioHealth to be Added to Russell 2000® and 3000® Indexes

Rhea-AI Summary

DarioHealth Corp. (Nasdaq: DRIO) announced its inclusion in the Russell 3000® and Russell 2000® Indexes, effective June 28, 2021, following the annual reconstitution. This inclusion reflects Dario's growth as a pioneer in digital therapeutics and is expected to enhance company visibility among institutional investors, as approximately $9 trillion in assets are benchmarked to Russell indexes. CEO Erez Raphael highlighted the achievement as a testament to the team's efforts in revolutionizing chronic disease management through AI-powered solutions.

Positive

• Inclusion in Russell 3000® and Russell 2000® Indexes expected to enhance visibility among institutional investors.
• Affirmation of Dario's status as a key player in the digital therapeutics market.

Negative

• None.

NEW YORK, June 15, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced it is set to join the broad-market Russell 3000^® Index and the small-cap Russell 2000^® Index at the conclusion of the Russell U.S. Indexes annual reconstitution, effective after the US equity markets open on Monday, June 28, 2021, according to a preliminary list of additions posted by FTSE Russell on Friday, June 4, 2021.

Annual reconstitution of the Russell indexes captures the 4,000 largest U.S. stocks as of May 7, 2021, ranking them by total market capitalization. Membership in the Russell 3000^® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000^® Index or small-cap Russell 2000^® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.

"Inclusion in the Russell indexes reflects the hard work and achievements of the entire Dario team as we work to build the premier digital health and therapeutics company," stated Erez Raphael, Chief Executive Officer of DarioHealth. "We look forward to a heightened awareness of our company that inclusion in these widely-followed indexes confers."

Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.

For more information on the Russell 3000® Index and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website: https://www.ftserussell.com/resources/russell-reconstitution

About DarioHealth Corp.

DarioHealth Corp. (Nasdaq: DRIO) is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. Dario's next-generation, AI-powered, digital therapeutic solutions support more than just an individual's disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions, intuitive, clinically proven digital tools, high-quality software, and coaching to help individuals improve health and sustain meaningful outcomes. Dario offers one of the highest-rated diabetes and hypertension solutions on the market. The company's cross-functional team operates at the intersection of life sciences, behavioral science, and software technology and is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users' health. Dario makes the right thing to do the easy thing to do. To learn more about DarioHealth and its digital health solutions, or for more information, visit http://dariohealth.com.    

About FTSE Russell:

FTSE Russell is a leading global index provider creating and managing a wide range of indexes, data and analytic solutions to meet client needs across asset classes, style and strategies. Covering 98% of the investable market, FTSE Russell indexes offer a true picture of global markets, combined with the specialist knowledge gained from developing local benchmarks around the world.

FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $16 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create investment funds, ETFs, structured products and index-based derivatives. FTSE Russell indexes also provide clients with tools for asset allocation, investment strategy analysis and risk management.

A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on index innovation and customer partnership applying the highest industry standards and embracing the IOSCO Principles. FTSE Russell is wholly owned by London Stock Exchange Group.

For more information, visit www.ftserussell.com 

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the expectation that the inclusion in the Russell Index will bring heightened awareness of the Company. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

DarioHealth Corporate Contact:
Suzanne Bedell
VP Marketing
suzanne@dariohealth.com
+1-347-767-4220

Investor Relations Contact:
Chuck Padala
chuck@lifesciadvisors.com
+1-646-627-8390

Media Contact:
Josephine Galatioto
Josephine.galatioto@russopartnersllc.com
+1-212-845-4262

View original content:http://www.prnewswire.com/news-releases/dariohealth-to-be-added-to-russell-2000-and-3000-indexes-301312310.html

SOURCE DarioHealth Corp.

FAQ

When will DarioHealth be added to the Russell Indexes?

DarioHealth will be added to the Russell 3000® and Russell 2000® Indexes on June 28, 2021.

What does DarioHealth's inclusion in the Russell Indexes signify for investors?

Inclusion in the Russell Indexes is expected to increase visibility and could attract more institutional investment.

How much is benchmarked against the Russell Indexes?

Approximately $9 trillion in assets are benchmarked against Russell's US indexes.

What are the Russell 3000® and Russell 2000® Indexes?

The Russell 3000® Index captures the 3,000 largest U.S. stocks, while the Russell 2000® Index includes the smallest 2,000 stocks from that group.

Who is the CEO of DarioHealth?

The CEO of DarioHealth is Erez Raphael.